S'abonner

Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study - 27/02/21

Doi : 10.1016/j.rmed.2021.106323 
Dejan Radovanovic a , Stefano Pini a, b , Elisa Franceschi a, b , Marica Pecis a , Andrea Airoldi a , Maurizio Rizzi a , Pierachille Santus a, b,
a Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Via G.B. Grassi 74, 20157, Milano, Italy 
b Department of Biomedical and Clinical Sciences (DIBIC), Università Degli Studi di Milano, Division of Respiratory Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli-Sacco, Via G.B. Grassi 74, 20157, Milano, Italy 

Corresponding author. Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Via G.B. Grassi, 74 - 20157, Milano, Italy.Division of Respiratory DiseasesOspedale L. SaccoASST Fatebenefratelli-SaccoVia G.B. GrassiMilano74 - 20157Italy

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

The therapeutic approach to COVID-19 and healthcare system preparedness improved during 2020. We compared characteristics and outcomes of hospitalized COVID-19 patients during the first 28 days of the March and October pandemic waves in Milan, Italy.

Material and methods

A prospective, observational study enrolling adult patients hospitalized with COVID-19 pneumonia during March 7-April 4 (1st period) and October 15-November 12 (2nd period). During the 1st period hydroxychloroquine, lopinavir/ritonavir and therapeutic enoxaparin when thrombosis was confirmed were administered; systemic corticosteroids were given in case of severe pneumonia. During the 2nd period dexamethasone, methylprednisolone, remdesivir, thromboprophylaxis or anticoagulation were administered according to international recommendations. Patients with respiratory distress on oxygen masks initiated CPAP. Outcomes were: length of hospital stay, all-cause in-hospital mortality and need for intubation.

Results

We included 70 patients (75% males) during the 1st and 76 patients (51% males, p = 0.522) during the 2nd period. Prevalence of severe respiratory failure (30% vs. 12%, p = 0.006), and D-dimer >3000 FEU (34% vs. 15%, P = 0.012) were reduced during the 2nd period, while anticoagulation and corticosteroids were more frequently administered (both p < 0.01). Mortality and time to referral were also reduced (39.4% vs. 22.4%, p = 0.019 and 6 vs. 5 days, p = 0.014), while need for intubation didn't change. Hospitalization length was comparable, but the proportion of patients discharged home was higher during the 2nd period (28.2% vs. 55.4%, p = 0.001).

Conclusions

Changing treatment paradigms and early referral might have reduced mortality in COVID-19 patients. The effects of specific therapeutic regimens needs further confirmation in future clinical studies.

Le texte complet de cet article est disponible en PDF.

Highlights

We compared patients' characteristics and outcomes during the 2020 1st and 2nd epidemic waves in Milan.
The proportion of patients with severe respiratory failure was higher during the 1st period.
Timing of referral and all-cause mortality were significantly decreased during the 2nd period.
Higher social awareness and change in treatment regimens may have promoted better outcomes during the 2nd pandemic wave.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, Respiratory failure, Pneumonia, Treatment, CPAP, Mortality

Abbreviations : COVID-19, CPAP, CRP, DNI, ED, FEU, FiO2, HDRU, Hb, IMV, LDH, LMWH, PaO2, PaCO2, PEEP, SaO2, WBC


Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 178

Article 106323- mars 2021 Retour au numéro
Article précédent Article précédent
  • Long-term exposure to fine particulate matter and hospitalization in COVID-19 patients
  • Angelico Mendy, Xiao Wu, Jason L. Keller, Cecily S. Fassler, Senu Apewokin, Tesfaye B. Mersha, Changchun Xie, Susan M. Pinney
| Article suivant Article suivant
  • Incidence of pulmonary embolism in patients with non-invasive respiratory support during COVID-19 outbreak
  • Jose Gregorio González-García, Sergi Pascual-Guardia, Ricardo J. Aguilar Colindres, Pilar Ausín Herrero, Mariela Alvarado Miranda, Mariela Arita Guevara, Diana Badenes Bonet, Salome Bellido Calduch, Oswaldo A. Caguana Vélez, Cinta Cumpli Gargallo, Marisol Dominguez-Alvarez, Joaquim Gea, Nuria Grau, Karys Khilzi, Juana Martínez-Llorens, Mónica Sánchez Ortiz, Albert Sánchez-Font, Antonio Sancho-Muñoz, Francisco José Parrilla-Gómez, Judith Marín Corral, Purificación Pérez Terán, Juan José Rodríguez-Sevilla, Roberto Chalela, Diego Rodríguez-Chiaradia

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.